Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20213812 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4CACNA2D1ADRB2ALOX12 | |
| SCHEMBL1687706 | 0.79 | KDM4E (0.36) | SLC6A2SLC6A4MAPKAPK2KDM4ELMNA | |
| SCHEMBL8557312 | 0.78 | ALDH1A1 (0.37) | SLC6A2SLC6A4CACNA2D1MAPKAPK2KDM4E | |
| SCHEMBL5803213 | 0.78 | ALDH1A1 (0.37) | SLC6A2SLC6A4CACNA2D1MAPKAPK2KDM4E | |
| SCHEMBL16357614 | 0.78 | SLC6A2 (0.35) | SLC6A2SLC6A4CACNA2D1MAPKAPK2ALOX12 | |
| SCHEMBL24087245 | 0.76 | CTSK (0.37) | SLC6A2SLC6A4MAPKAPK2KDM4ELMNA | |
| SCHEMBL2087810 | 0.75 | ALDH1A1 (0.34) | SLC6A2SLC6A4CACNA2D1MAPKAPK2KDM4E | |
| SCHEMBL24087824 | 0.75 | KDM4E (0.35) | SLC6A2SLC6A4CACNA2D1MAPKAPK2KDM4E | |
| SCHEMBL4312352 | 0.75 | — | — | |
| SCHEMBL1532491 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | SLC6A2 3744/4885SLC6A4 4189/4885CACNA2D1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.